Literature DB >> 20119985

Reduction of periprosthetic infection with silver-coated megaprostheses in patients with bone sarcoma.

Jendrik Hardes1, Christof von Eiff, Arne Streitbuerger, Maurice Balke, Tymoteus Budny, Marcel P Henrichs, Gregor Hauschild, Helmut Ahrens.   

Abstract

BACKGROUND AND OBJECTIVES: The placement of megaprostheses in patients with bone sarcoma is associated with high rates of infection, despite prophylactic antibiotic administration. In individual cases, secondary amputation is unavoidable in the effort to cure infection.
METHODS: The infection rate in 51 patients with sarcoma (proximal femur, n = 22; proximal tibia, n = 29) who underwent placement of a silver-coated megaprosthesis was assessed prospectively over a 5-year period, along with the treatment administered for infection. The infection rate was compared with the data for 74 patients in whom an uncoated titanium megaprosthesis (proximal femur, n = 33; proximal tibia, n = 41) was implanted.
RESULTS: The infection rate was substantially reduced from 17.6% in the titanium to 5.9% in the silver group. Whereas 38.5% of patients in the titanium group ultimately had to undergo amputation when periprosthetic infection developed, these mutilating surgical procedures were not necessary in the study group.
CONCLUSIONS: The use of silver-coated prostheses reduced the infection rate in the medium term. In addition, less aggressive treatment of infection was possible in the group with silver-coated prostheses. Further studies with longer term follow-up periods and larger numbers of patients are warranted in order to confirm these encouraging results.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20119985     DOI: 10.1002/jso.21498

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  95 in total

Review 1.  [New surgical treatment options for bone tumors].

Authors:  D Andreou; M P Henrichs; G Gosheger; M Nottrott; A Streitbürger; J Hardes
Journal:  Pathologe       Date:  2014-11       Impact factor: 1.011

2.  Distal femur and proximal tibia replacement with megaprosthesis in revision knee arthroplasty: a limb-saving procedure.

Authors:  Steffen Höll; Annabel Schlomberg; Georg Gosheger; Ralf Dieckmann; Arne Streitbuerger; Dino Schulz; Jendrik Hardes
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2012-03-06       Impact factor: 4.342

Review 3.  [Antimicrobial prosthesis coatings].

Authors:  S Gravius; D C Wirtz
Journal:  Orthopade       Date:  2015-12       Impact factor: 1.087

Review 4.  Management of infection following reconstruction in bone tumors.

Authors:  Sudhir K Kapoor; Rajesh Thiyam
Journal:  J Clin Orthop Trauma       Date:  2015-07-07

Review 5.  Silver-coated megaprostheses: review of the literature.

Authors:  Tom Schmidt-Braekling; Arne Streitbuerger; Georg Gosheger; Friedrich Boettner; Markus Nottrott; Helmut Ahrens; Ralf Dieckmann; Wiebke Guder; Dimosthenis Andreou; Gregor Hauschild; Burkhard Moellenbeck; Wenzel Waldstein; Jendrik Hardes
Journal:  Eur J Orthop Surg Traumatol       Date:  2017-03-06

6.  Causes and Frequencies of Reoperations After Endoprosthetic Reconstructions for Extremity Tumor Surgery: A Systematic Review.

Authors:  Patrick Thornley; Matias Vicente; Austin MacDonald; Nathan Evaniew; Michelle Ghert; Roberto Velez
Journal:  Clin Orthop Relat Res       Date:  2019-04       Impact factor: 4.176

Review 7.  Megaprosthesis versus Allograft Prosthesis Composite for massive skeletal defects.

Authors:  Deepak Gautam; Rajesh Malhotra
Journal:  J Clin Orthop Trauma       Date:  2017-09-25

8.  [Tumor prostheses : Important in modern revision arthroplasty].

Authors:  A Hillmann; I Ipach
Journal:  Orthopade       Date:  2015-05       Impact factor: 1.087

9.  Megaprostheses in the management of trauma of the knee.

Authors:  Scott Evans; Edward Laugharne; Amit Kotecha; Laura Hadley; Arul Ramasamy; Lee Jeys
Journal:  J Orthop       Date:  2015-12-07

10.  Treatment solutions are unclear for perimegaprosthetic infections.

Authors:  Lisa B Ercolano; Tyson Christensen; Richard McGough; Kurt Weiss
Journal:  Clin Orthop Relat Res       Date:  2013-10       Impact factor: 4.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.